...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and vaccine immunology: CVI >Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines
【24h】

Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines

机译：联合使用b型流感嗜血杆菌脑膜炎奈瑟氏球菌血清群C结合疫苗与白喉-破伤风-无细胞百日咳和肺炎球菌结合疫苗联合接种后5年中儿童的抗体持久性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We evaluated antibody persistence in children up to 5 years after administration of a combined Haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C (MenC)-tetanus toxoid (TT) conjugate vaccine coadministered with a pneumococcal conjugate vaccine. This is the follow-up study of a randomized trial (ClinicalTrials.gov registration no. NCT00334334/00463437) in which healthy children were vaccinated (primary vaccinations at 2, 4, and 6 months of age and booster vaccination at 11 to 18 months of age) with Hib-MenC-TT or a control MenC conjugate vaccine, coadministered with diphtheria-tetanus-acellular pertussis (DTPa)-based combination vaccines (DTPa/Hib for control groups) and a pneumococcal conjugate vaccine (10-valent pneumococcal nontypeable H. influenzae protein D conjugate vaccine [PHiD-CV] or 7-valent cross-reacting material 197 [CRM197] conjugate vaccine [7vCRM]). MenC antibody titers were measured with a serum bactericidal antibody (SBA) assay using rabbit complement (i.e., rabbit SBA [rSBA]), and antibodies against Hib polyribosylribitol phosphate (PRP) were measured with an enzyme-linked immunosorbent assay. Antibody persistence up to 5 years after booster vaccination is reported for 530 children ～6 years of age. The percentages of children with seroprotective rSBA-MenC titers were between 24.2% and 40.1% in all groups approximately 5 years after booster vaccination. More than 98.5% of children in each group retained seroprotective anti-PRP concentrations. No vaccine-related serious adverse events and no events related to a lack of vaccine efficacy were reported. Approximately 5 years after booster vaccination, the majority of children retained seroprotective anti-PRP antibody concentrations. The percentage of children retaining seroprotective rSBA-MenC titers was low (≤40%), suggesting that a significant proportion of children may be unprotected against MenC disease. (This study has been registered at ClinicalTrials.gov under registration no. NCT00891176.)
机译：我们在联合使用b型流感嗜血杆菌（Hib）-脑膜炎奈瑟氏球菌血清群C（MenC）-破伤风类毒素（TT）结合疫苗与肺炎球菌结合疫苗联合使用后，评估了儿童长达5年的抗体持久性。这是一项随机试验的后续研究（ClinicalTrials.gov注册号NCT00334334 / 00463437），其中对健康的儿童进行了疫苗接种（在2、4、4和6个月大时进行初次疫苗接种，并在11到18个月进行初次疫苗接种）年龄）与Hib-MenC-TT或对照MenC结合疫苗，与基于白喉-破伤风-无细胞百日咳（DTPa）的联合疫苗（对照组为DTPa / Hib）和肺炎球菌结合疫苗（10价肺炎球菌不可分型H）流感病毒蛋白D结合疫苗[PHiD-CV]或7价交叉反应材料197 [CRM 197 ]结合疫苗[7vCRM]）。使用兔补体（即兔SBA [rSBA]），通过血清杀菌抗体（SBA）测定法测定MenC抗体效价，并通过酶联免疫吸附测定法测定针对Hib聚核糖核糖醇磷酸酯（PRP）的抗体。据报道，有530名〜6岁的儿童在加强免疫后长达5年的抗体持久性。加强免疫后约5年，所有组中具有血清保护性rSBA-MenC滴度的儿童百分比在24.2％至40.1％之间。每组中超过98.5％的儿童保留了血清保护性抗PRP浓度。没有报道与疫苗有关的严重不良事件，也没有与缺乏疫苗功效有关的事件。加强疫苗接种大约5年后，大多数儿童保留了血清保护性抗PRP抗体浓度。保留血清保护性rSBA-MenC滴度的儿童比例很低（≤40％），这表明很大一部分儿童可能没有针对MenC疾病的保护。 （该研究已在ClinicalTrials.gov上注册，注册号为NCT00891176。）

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号